Key result
Liposomal doxorubicin formulations demonstrated similar efficacy and favorable toxicity profiles compared with conventional doxorubicin in patients with metastatic breast cancer.
Why the study?
Do liposomal anthracyclines provide similar efficacy with improved tolerability compared to conventional anthracyclines in patients with breast cancer?
Population
Patients with breast cancer (metastatic, locally advanced, and early-stage)
Comparison
Liposomal anthracyclines vs Conventional anthracyclines
Design
Review
Authors
Loading...
May guide anthracycline selection in metastatic breast cancer; leaves open randomized evaluation in adjuvant settings.
Do liposomal anthracyclines provide similar efficacy with improved tolerability compared to conventional anthracyclines in patients with breast cancer?
Liposomal anthracyclines offer similar efficacy and improved tolerability (including reduced cardiotoxicity) compared to conventional doxorubicin in breast cancer, supporting their investigation as adjuvant therapy.
Susana M. Campos (2003) conducted a review in Breast Cancer. Liposomal anthracyclines vs. Conventional doxorubicin was evaluated. Liposomal doxorubicin formulations demonstrated similar efficacy and favorable toxicity profiles compared with conventional doxorubicin in patients with metastatic breast cancer.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: